Randomized Controlled Trial
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 7, 2014; 20(29): 10151-10157
Published online Aug 7, 2014. doi: 10.3748/wjg.v20.i29.10151
Table 2 Distribution of specific risk factors in the investigated population (n = 665) n (%)
Risk factorsIndomethacingroup (n = 347)Control group(n = 318)P value
Age < 50 yr (n = 104)57/347 (16.4)47/318 (14.8)0.559
Female gender (n = 426)214/347 (61.7)212/318 (66.7)0.180
BMI > 25 (n = 362)191/347 (55.0)171/318 (53.8)0.743
Duration of ERCP > 20 min (n = 211)111/347 (32.0)100/318 (31.4)0.880
Non-dilated bile duct (n = 299)158/347 (45.5)141/318 (44.3)0.757
Pancreatic duct opacification (n = 463)246/347 (70.1)217/318 (68.2)0.534
EST biliary (n = 443)224/347 (64.6)219/318 (68.9)0.195
EST pancreatic/double (n = 48)20/347 (5.8)28/318 (8.8)0.130
Difficult cannulation (n = 116)64/347 (18.4)52/318 (16.4)0.111
Gallstone extraction (n = 165)82/347 (23.6)83/318 (26.1)0.461
Bile duct dilatation (n = 22)11/347 (3.2)11/318 (3.5)0.835
Biliary plastic stent placement (n = 75)35/347 (10.1)40/318 (12.6)0.640
Total (n = 2734)1413/4164 (33.9)1321/3816 (34.6)0.520